5. Intangible and Other Assets, Net

Intangible and other assets, net, were comprised of the following at December 31, 2014 and 2013:


*In thousands*	2014			2013
Capitalized patent and license costs	$	5,975		$	5,975
Less accumulated amortization		(5,036	)		(5,007	)

		939			968
Inventory, non-current		460			2,985
Other assets		2,494			1,861

	$	3,893		$	5,814

Amortization expense for intangible assets was $29,000, $25,000 and $218,000 in 2014, 2013 and 2012, respectively. The weighted average amortization period for intangible assets was 17.0 years, for each of 2014, 2013 and 2012, respectively. The estimated future amortization expense is $31,000 per year for 2015, 2016, 2017, 2018 and 2019 and $241,000 thereafter.

In 2012, the Company recorded charges to operating expenses of $5.2 million to reflect impairment of the carrying value of certain capitalized patents and licenses or purchased technology. This amount included a charge of $4.8 million to reflect impairment of the carrying value of intangible assets associated with ridaforolimus, following the decision in June 2012 by the FDA not to approve the NDA filed by Merck for the treatment of patients with soft tissue or bone sarcomas. The impairment of the carrying value of intangible assets was based on management’s assessment of the uncertainty related to the timing and amount of future cash flows anticipated from these assets. No impairment charges were recorded in 2014 or 2013.